

Ramzi M Mohammad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1596524/publications.pdf>

Version: 2024-02-01

110
papers

4,337
citations

101543

36
h-index

123424

61
g-index

116
all docs

116
docs citations

116
times ranked

6790
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad targeting of resistance to apoptosis in cancer. <i>Seminars in Cancer Biology</i> , 2015, 35, S78-S103.	9.6	535
2	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304.	9.6	220
3	The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines. <i>Blood</i> , 1997, 90, 4307-4312.	1.4	179
4	Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. <i>Clinical Cancer Research</i> , 2007, 13, 2226-2235.	7.0	147
5	Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. <i>Current Vascular Pharmacology</i> , 2017, 15, 339-351.	1.7	143
6	The nuclear export protein XPO1 "from biology to targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 152-169.	27.6	114
7	Nonpeptidic small molecule inhibitors against Bcl-2 for cancer therapy. <i>Journal of Cellular Physiology</i> , 2009, 218, 13-21.	4.1	109
8	Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice. <i>Gastroenterology</i> , 2013, 144, 447-456.	1.3	109
9	Targeting acute myeloid leukemia stem cell signaling by natural products. <i>Molecular Cancer</i> , 2017, 16, 13.	19.2	104
10	Emerging Bcl-2 inhibitors for the treatment of cancer. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 59-70.	2.4	92
11	Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF- κ B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. <i>Oncotarget</i> , 2016, 7, 78883-78895.	1.8	92
12	TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Induces Apoptosis in Pancreatic Cancer: Involvement of Notch-1 Signaling Pathway. <i>Cancer Research</i> , 2009, 69, 2757-2765.	0.9	78
13	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. <i>Molecular Cancer</i> , 2009, 8, 115.	19.2	71
14	Snail nuclear transport: The gateways regulating epithelial-to-mesenchymal transition?. <i>Seminars in Cancer Biology</i> , 2014, 27, 39-45.	9.6	70
15	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 76-87.	4.1	69
16	Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. <i>Molecular Cancer</i> , 2008, 7, 20.	19.2	68
17	Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 13-21.	4.1	67
18	Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. <i>Haematologica</i> , 2013, 98, 1098-1106.	3.5	59

#	ARTICLE	IF	CITATIONS
19	Nonpeptidic Small-Molecule Inhibitor of Bcl-2 and Bcl-XL, (???)-Gossypol, Enhances Biological Effect of Genistein Against BxPC-3 Human Pancreatic Cancer Cell Line. <i>Pancreas</i> , 2005, 31, 317-324.	1.1	56
20	Chemoprevention of Pancreatic Cancer: Characterization of Par-4 and its Modulation by 3,3'-Diindolylmethane (DIM). <i>Pharmaceutical Research</i> , 2008, 25, 2117-2124.	3.5	56
21	Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 4038-4045.	7.0	53
22	Epidermal Growth Factor Receptor-Related Protein Inhibits Cell Growth and Invasion in Pancreatic Cancer. <i>Cancer Research</i> , 2006, 66, 7653-7660.	0.9	51
23	Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. <i>Leukemia Research</i> , 1995, 19, 667-673.	0.8	49
24	Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, etoposide) Tj ETQq0 0 0 rgBT /Overlock 10	4.1	49
25	Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents. <i>Cancers</i> , 2011, 3, 428-445.	3.7	48
26	Involvement of F-BOX proteins in progression and development of human malignancies. <i>Seminars in Cancer Biology</i> , 2016, 36, 18-32.	9.6	48
27	Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. <i>Oncotarget</i> , 2014, 5, 3444-3454.	1.8	47
28	Anticancer potential of sanguinarine for various human malignancies. <i>Future Medicinal Chemistry</i> , 2017, 9, 933-950.	2.3	45
29	Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors. <i>Oncotarget</i> , 2011, 2, 378-392.	1.8	45
30	Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. <i>Oncotarget</i> , 2017, 8, 82144-82155.	1.8	43
31	Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. <i>Scientific Reports</i> , 2017, 7, 44125.	3.3	42
32	Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2008, 7, 1418-1426.	3.4	40
33	Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention. <i>Current Drug Targets</i> , 2013, 14, 1094-1100.	2.1	40
34	Gastrointestinal stromal tumor: a review of current and emerging therapies. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 625-641.	5.9	39
35	Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2884-2893.	4.1	37
36	Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2010, 10, 319-331.	1.6	37

#	ARTICLE	IF	CITATIONS
37	Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. <i>Journal of Translational Medicine</i> , 2016, 14, 69.	4.4	36
38	Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells. <i>PLoS ONE</i> , 2017, 12, e0180895.	2.5	36
39	Establishment of a Human Pancreatic Tumor Xenograft Model. <i>Pancreas</i> , 1998, 16, 19-25.	1.1	35
40	Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. <i>Cancers</i> , 2011, 3, 1527-1549.	3.7	31
41	Potential therapeutic targets of Guggulsterone in cancer. <i>Nutrition and Metabolism</i> , 2017, 14, 23.	3.0	31
42	F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. <i>Seminars in Cancer Biology</i> , 2016, 36, 95-104.	9.6	29
43	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44295-44311.	1.8	29
44	Transactivator of transcription-tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1661-1672.	4.1	28
45	Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. <i>Scientific Reports</i> , 2015, 5, 16077.	3.3	28
46	Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. <i>Cancer Letters</i> , 2016, 383, 309-317.	7.2	28
47	Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay. <i>Journal of Translational Medicine</i> , 2016, 14, 140.	4.4	28
48	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1338-1348.	7.0	28
49	Potential of 2-Chlorodeoxyadenosine Activity by Bryostatin 1 in the Resistant Chronic Lymphocytic Leukemia Cell Line (WSU-CLL): Association with Increased Ratios of dCK/5'-NT and Bax/Bcl-2. <i>Biological Chemistry</i> , 1998, 379, 1253-1262.	2.5	27
50	The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2016, 5, 59.	2.4	27
51	Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. <i>Cancers</i> , 2020, 12, 750.	3.7	27
52	Small-Molecule Inhibitors of Bcl-2 Family Proteins as Therapeutic Agents in Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 20-30.	1.6	26
53	SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. <i>Journal of Hematology and Oncology</i> , 2009, 2, 8.	17.0	26
54	Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. <i>Small GTPases</i> , 2019, 10, 367-377.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Induction of apoptosis in breast cancer cells by TPA. <i>Oncogene</i> , 1998, 17, 2915-2920.	5.9	25
56	Obesity-induced MBD 2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells. <i>Molecular Oncology</i> , 2019, 13, 894-908.	4.6	24
57	Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 237.	4.1	23
58	Preclinical Studies of Apogossypolone, a Novel Pan Inhibitor of Bcl-2 and Mcl-1, Synergistically Potentiates Cytotoxic Effect of Gemcitabine in Pancreatic Cancer Cells. <i>Pancreas</i> , 2010, 39, 323-331.	1.1	22
59	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 1902.	3.7	22
60	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 535-546.	1.8	22
61	The Molecular Genetics of Autosomal Recessive Nonsyndromic Intellectual Disability: a Mutational Continuum and Future Recommendations. <i>Annals of Human Genetics</i> , 2016, 80, 342-368.	0.8	21
62	Targeting Cancer at the Nuclear Pore. <i>Journal of Clinical Oncology</i> , 2016, 34, 4180-4182.	1.6	18
63	Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. <i>Scientific Reports</i> , 2019, 9, 1554.	3.3	18
64	Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. <i>Cancers</i> , 2021, 13, 2777.	3.7	18
65	Conversion of high grade lymphoma tumor cell line to intermediate grade with tpa and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. <i>Hematological Oncology</i> , 1990, 8, 81-89.	1.7	17
66	PAR-4 as a possible new target for pancreatic cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 611-620.	3.4	17
67	Nuclear Export Inhibition for Pancreatic Cancer Therapy. <i>Cancers</i> , 2018, 10, 138.	3.7	17
68	Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 3307-3316.	7.0	17
69	Dysregulated expression of SKP2 and its role in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2018, 59, 1051-1063.	1.3	16
70	Cholesterol Depletion Alters Cardiomyocyte Subcellular Signaling and Increases Contractility. <i>PLoS ONE</i> , 2016, 11, e0154151.	2.5	15
71	Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. <i>Clinical Cancer Research</i> , 2002, 8, 1277-83.	7.0	15
72	I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. <i>Molecular Cancer</i> , 2010, 9, 228.	19.2	14

#	ARTICLE	IF	CITATIONS
73	Role of leptin and leptin receptors in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 10-16.	1.3	14
74	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1836-1845.	4.1	14
75	Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. <i>Cancers</i> , 2021, 13, 4161.	3.7	14
76	Therapeutic Potential of Resveratrol in Lymphoid Malignancies. <i>Nutrition and Cancer</i> , 2016, 68, 365-373.	2.0	13
77	DNAJB3 attenuates metabolic stress and promotes glucose uptake by eliciting Glut4 translocation. <i>Scientific Reports</i> , 2019, 9, 4772.	3.3	12
78	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C Mutant Cancers. <i>Cancer Research Communications</i> , 2022, 2, 342-352.	1.7	12
79	Induced expression of A monocytoid B lymphocyte antigen phenotype on the reh cell line. <i>American Journal of Hematology</i> , 1990, 33, 153-159.	4.1	11
80	A human b-cell lymphoma line with a de novo multidrug resistance phenotype. <i>Cancer</i> , 1992, 69, 1468-1474.	4.1	11
81	Modulation of cIAP-1 by Novel Antitubulin Agents When Combined with Bryostatin 1 Results in Increased Apoptosis in the Human Early Pre-B Acute Lymphoblastic Leukemia Cell Line Reh. <i>Biochemical and Biophysical Research Communications</i> , 1999, 266, 76-80.	2.1	10
82	Rituximab, Cyclophosphamide, Dexamethasone (RCD) Regimen Induces Cure in WSU-WM Xenograft Model and a Partial Remission in Previously Treated Waldenström's Macroglobulinemia Patient. <i>Journal of Drug Targeting</i> , 2002, 10, 405-411.	4.4	10
83	Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin's Xenograft Animal Models: Preclinical Evaluation.. <i>Blood</i> , 2007, 110, 2339-2339.	1.4	10
84	DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2019, 11, 1101.	3.7	9
85	Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. <i>Heliyon</i> , 2019, 5, e02290.	3.2	8
86	PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma. <i>Cancers</i> , 2022, 14, 160.	3.7	8
87	Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for <i>Helicobacter pylori</i> eradication: A prospective randomized study. <i>Turkish Journal of Gastroenterology</i> , 2018, 29, 549-554.	1.1	7
88	Treatment-induced Expression of Anti-apoptotic Proteins in WSU-CLL, a Human Chronic Lymphocytic Leukemia Cell Line. <i>Journal of Drug Targeting</i> , 2001, 9, 329-339.	4.4	6
89	Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo. <i>Blood</i> , 2016, 128, 4131-4131.	1.4	6
90	Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 598-598.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy. Journal of Stem Cell Research & Therapy, 2013, 01, .	0.3	5
92	Expression of a New Cellular Protein by Monocytoid B-Lymphocytes Differentiated from the Acute Lymphoblastic Leukemia Cell Line (REH). Leukemia and Lymphoma, 1991, 4, 277-284.	1.3	3
93	Protein study of T and B acute lymphoblastic leukemia cell lines. Electrophoresis, 1994, 15, 1218-1224.	2.4	3
94	Protein studies of human non-Hodgkin's B-lymphoma: Appraisal by two-dimensional gel electrophoresis. Electrophoresis, 1994, 15, 1566-1572.	2.4	3
95	Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study. Blood, 2020, 136, 11-12.	1.4	2
96	Systems and Network Pharmacology Strategies for Pancreatic Ductal Adenocarcinoma Therapy. , 2014, , 405-425.		1
97	Airway surface liquid volume expansion induces rapid changes in amiloride-sensitive Na ⁺ transport across upper airway epithelium-Implications concerning the resolution of pulmonary edema. Physiological Reports, 2015, 3, e12453.	1.7	1
98	Abstract B38: Clinical translation of nuclear export inhibitor in metastatic pancreatic cancer. , 2016, , .		1
99	Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome. Annals of Translational Medicine, 2015, 3, 312.	1.7	1
100	Embelin-Mediated Apoptosis in Leukemic Cells via Generation of Reactive Oxygen Species. , 2016, , .		0
101	Network Pharmacology: An Emerging Area in Anti-Cancer Drug Discovery. , 2012, , 393-418.		0
102	Pristimerin Inhibits Growth and Induces Apoptosis in Human Colorectal Cancer Cells Through the Generation of Reactive Oxygen Species. , 2016, , .		0
103	Bortezomib Mediated Downregulation of F-box Protein, S-phase Kinase-Associated Protein 2 (SKP2) Causes Apoptotic Cell Death in Chronic Myelogenous Leukemia Cells. , 2016, , .		0
104	Novel Mitochondrial-Derived Peptide MOTS-c Inhibits Adipogenesis through Down Regulation of Master Gene PPAR in Murine Adipocytes. , 2016, , .		0
105	Molecular and Peritoneal Microvascular Changes Cause Peritoneal Membrane Dysfunction by Uremia-Related Mechanisms. , 2016, , .		0
106	The MetaQ â€“ a Platform for Targeted Metabolomics Studies in Qatar. , 2016, , .		0
107	Db/db Obese Mice Exhibit Enhanced Phosphorylation of p38, ERK1/2 and AKT in the Kidney. FASEB Journal, 2018, 32, .	0.5	0
108	Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma. Blood, 2021, 138, 683-683.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Comprehensive analysis of circulating miRNA expression profiles in insulin resistance and type 2 diabetes in Qatari population. <i>International Journal of Transgender Health</i> , 2022, 15, 191-202.	2.3	0
110	Abstract 5315: Anti-tumor activity of KRASG12C inhibitors is enhanced when combined with Cdc42 effector p21-activated kinase 4 targeting agents. <i>Cancer Research</i> , 2022, 82, 5315-5315.	0.9	0